©2025 Stanford Medicine
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
Not Recruiting
Trial ID: NCT00766116
Purpose
This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.
Official Title
A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML
Stanford Investigator(s)
Lauren Maeda
Clinical Associate Professor, Medicine - Oncology
Rondeep Brar
Clinical Professor, Medicine - Hematology
Eligibility
Inclusion Criteria:
* Diagnosis of Relapsed AML
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and life expectancy \> 3 months
* ≥ 18 years old
* Previously untreated for current AML relapse
* Adequate organ function
* Written informed consent
Exclusion Criteria:
* Pregnant or breast-feeding women
* Growth factors that support platelet or white cell number or function must not have been administered within the past 7 days
* Currently receiving another investigational drug
* Currently receiving other anti-cancer agents
* Uncontrolled infection
* HIV positive
* Received previous therapy with either Mylotarg or 5-azacitidine
Intervention(s):
drug: 5-Azacitidine
drug: Gemtuzumab ozogamicin
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061